Mesothelin-Targeted Thorium-227 Conjugate (MSLN-TTC): Preclinical Evaluation of a New Targeted Alpha Therapy for Mesothelin-Positive Cancers

MLA

Alan Cuthbertson, et al. “Mesothelin-Targeted Thorium-227 Conjugate (MSLN-TTC): Preclinical Evaluation of a New Targeted Alpha Therapy for Mesothelin-Positive Cancers.” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, vol. 25, no. 15, Oct. 2018. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....bf561b095603992bd69dc2171ad5c243&authtype=sso&custid=ns315887.

APA

Alan Cuthbertson, Steinar R. Uran, Karl Ziegelbauer, Sven Golfier, Christoph A. Schatz, Alexander Kristian, Anne Mobergslien, Christoph Kneip, Hartwig Hennekes, Urs B. Hagemann, Christine Ellingsen, Katrine Wickstroem, Roger Smeets, Véronique Cruciani, Roger M. Bjerke, Dominik Mumberg, Jenny Karlsson, Olav B. Ryan, & Joachim Schuhmacher. (2018). Mesothelin-Targeted Thorium-227 Conjugate (MSLN-TTC): Preclinical Evaluation of a New Targeted Alpha Therapy for Mesothelin-Positive Cancers. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 25(15).

Chicago

Alan Cuthbertson, Steinar R. Uran, Karl Ziegelbauer, Sven Golfier, Christoph A. Schatz, Alexander Kristian, Anne Mobergslien, et al. 2018. “Mesothelin-Targeted Thorium-227 Conjugate (MSLN-TTC): Preclinical Evaluation of a New Targeted Alpha Therapy for Mesothelin-Positive Cancers.” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 25 (15). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....bf561b095603992bd69dc2171ad5c243&authtype=sso&custid=ns315887.